Skip header and navigation

Refine By

170 records – page 1 of 17.

[A case from general practice (10): Acute diarrhea during foreign travel].

https://arctichealth.org/en/permalink/ahliterature220873
Source
Z Arztl Fortbild (Jena). 1993 Jun 12;87(6):523-4
Publication Type
Article
Date
Jun-12-1993
Author
H. Berndt
Author Affiliation
Klinik für Innere Medizin (Charité), Humboldt-Universität, Berlin.
Source
Z Arztl Fortbild (Jena). 1993 Jun 12;87(6):523-4
Date
Jun-12-1993
Language
German
Publication Type
Article
Keywords
Adult
Diagnosis, Differential
Diarrhea - etiology
Duodenal Ulcer - complications - diagnosis
Humans
Male
Moscow
Peptic Ulcer Hemorrhage - complications - diagnosis
Travel
PubMed ID
8333219 View in PubMed
Less detail

Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis.

https://arctichealth.org/en/permalink/ahliterature22339
Source
Ann Oncol. 1997 Jan;8(1):65-70
Publication Type
Article
Date
Jan-1997
Author
J. Norum
B. Vonen
J A Olsen
A. Revhaug
Author Affiliation
Department of Oncology, University of Tromsø, Norway.
Source
Ann Oncol. 1997 Jan;8(1):65-70
Date
Jan-1997
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - economics - therapeutic use
Chemotherapy, Adjuvant - economics
Colorectal Neoplasms - drug therapy - economics - mortality - pathology - surgery
Colostomy
Cost-Benefit Analysis
Female
Fluorouracil - administration & dosage - economics
Follow-Up Studies
Health Care Costs
Humans
Length of Stay - economics
Levamisole - administration & dosage - economics
Male
Middle Aged
Norway - epidemiology
Quality of Life
Research Support, Non-U.S. Gov't
Survival Analysis
Survival Rate
Travel - economics
Abstract
BACKGROUND: Adjuvant chemotherapy (5-fluorouracil, levamisole) is now standard practice in the treatment of Dukes' B and C coloretal carcinoma (CRC), and this has increased the financial burden on health care systems world-wide. PATIENTS AND METHODS: Between 1993 and 1996, 95 patients in northern Norway were included in a national randomised CRC study, and assigned to surgery plus adjuvant chemotherapy or surgery alone. In April 1996, 94 of the patients were evaluable and 82 were still alive. The total treatment costs (hospital stay, surgery, chemotherapy, administrative and travelling costs) were calculated. A questionnaire was mailed to all survivors for assessment of the quality of their lives (QoL) (EuroQol questionnaire, a simple QoL-scale, global QoL-measure of the EORTC QLQ-C30), and 62 of them (76%) responded. RESULTS: Adjuvant chemotherapy in Dukes' B and C CRC raised the total treatment costs by 3,369 pounds. The median QoL was 0.83 (0-1 scale) in both arms. Employing a 5% discount rate and an improved survival of adjuvant therapy ranging from 5% to 15%, we calculated the cost of one gained quality-adjusted life-year (QALY) to be between 4,800 pounds and 16,800 pounds. CONCLUSION: Using a cut-off point level of 20,000 pounds per QALY, adjuvant chemotherapy in CRC appears to be cost-effective only when the improvement in 5-year survival is > or = 5%. Adjuvant chemotherapy does not affect short-term QoL.
PubMed ID
9093709 View in PubMed
Less detail

Adverse reactions to Japanese encephalitis vaccine in travellers.

https://arctichealth.org/en/permalink/ahliterature34893
Source
J Infect. 1996 Mar;32(2):119-22
Publication Type
Article
Date
Mar-1996
Author
H D Nothdurft
T. Jelinek
A. Marschang
H. Maiwald
A. Kapaun
T. Löscher
Author Affiliation
Department of Infectious Diseases and Tropical Medicine, University of Munich, Germany.
Source
J Infect. 1996 Mar;32(2):119-22
Date
Mar-1996
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Child
Child, Preschool
Encephalitis Viruses, Japanese - immunology
Female
Humans
Male
Middle Aged
Travel
Vaccination - adverse effects
Viral Vaccines - adverse effects
Abstract
Vaccination against Japanese Encephalitis (JE) has been carried out extensively in many Asian countries for the past 20 years. The vaccine was generally considered to be effective and of low reactogenity. However, since 1989 an unusual number of systemic reactions characterized mainly by generalized urticaria and/or angioedema following JE vaccination were reported from Australia, Canada and Denmark, 860 travellers were recruited during a period of 16 months for a prospective study with the aim to investigate the type and incidence of side effects following JE vaccination (JEV) in German travellers. 826 received a primary immunization (2 injections at days 0 and 7-14) and 34 received a single booster injection. A detailed standardized questionnaire was distributed to all vaccinees after the first injection. A total of 509 questionnaires could be evaluated, which represents a return rate of 59.2%. 46% of the vaccinees reported about no adverse events at all. 54% reported about one or more adverse effects. Local reactions at the injection site were observed by 209 vaccinees, while 65 reported about systemic side effects like headache, fever, dizziness and generalized rash. There was no significant difference following first or second injection of the primary immunization or the booster injection, respectively, regarding incidence, severity or type of side effects. 2.2% of the vaccinees reporting reactions sought medical advice and 1.8% were judged unfit for work for an average of 2.2 days. The amount of systemic reactions might indicate a potential hazard of serious anaphylactic reactions. Unlike hepatitis A. Japanese encephalitis is an extremely rare disease in travellers. Therefore, the risk of acquiring the disease when travelling to affected areas without prior immunization should be considered against the risk of developing serious side effects after vaccination. We conclude that JEV should remain restricted to travellers with an increased risk of acquiring JE.
PubMed ID
8708368 View in PubMed
Less detail
Source
Tidsskr Nor Laegeforen. 1991 Jun 20;111(16):2006-7
Publication Type
Article
Date
Jun-20-1991
Author
E. Lien
Source
Tidsskr Nor Laegeforen. 1991 Jun 20;111(16):2006-7
Date
Jun-20-1991
Language
Norwegian
Publication Type
Article
Keywords
Brazil - epidemiology
Disease Outbreaks
Humans
Norway - epidemiology
Ships
Travel
Tropical Climate
Typhoid Fever - epidemiology - transmission
PubMed ID
1866743 View in PubMed
Less detail

[A new vaccine against hepatitis A can substitute gamma globulin prevention for travellers abroad]

https://arctichealth.org/en/permalink/ahliterature56853
Source
Lakartidningen. 1992 Sep 16;89(38):3029-30
Publication Type
Article
Date
Sep-16-1992
Author
S. Iwarson
Author Affiliation
Infektionskliniken, Ostra sjukhuset, Göteborg.
Source
Lakartidningen. 1992 Sep 16;89(38):3029-30
Date
Sep-16-1992
Language
Swedish
Publication Type
Article
Keywords
Hepatitis A - prevention & control
Humans
Sweden
Travel
Viral Hepatitis Vaccines - administration & dosage
gamma-Globulins - administration & dosage
PubMed ID
1383653 View in PubMed
Less detail

An international outbreak of Vero cytotoxin-producing Escherichia coli O157 infection amongst tourists; a challenge for the European infectious disease surveillance network

https://arctichealth.org/en/permalink/ahliterature33056
Source
Epidemiol Infect. 1999 Oct;123(2):217-23
Publication Type
Article
Date
Oct-1999
Author
Pebody, RG
Furtado, C
Rojas, A
McCarthy, N
Nylen, G
Ruutu, P
Leino, T
Chalmers, R
de Jong, B
Donnelly, M
Fisher, I
Gilham, C
Graverson, L
Cheasty, T
Willshaw, G
Navarro, M
Salmon, R
Leinikki, P
Wall, P
Bartlett, C
Author Affiliation
European Programme for Intervention Epidemiology Training, National Public Health Institute, Helsinki, Finland
Source
Epidemiol Infect. 1999 Oct;123(2):217-23
Date
Oct-1999
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Bacterial Toxins - biosynthesis
Case-Control Studies
Child
Child, Preschool
Disease Notification
Disease Outbreaks
Enterotoxins - biosynthesis
Escherichia coli Infections - epidemiology
Escherichia coli O157 - metabolism
Europe - epidemiology
Female
Humans
Infant
Male
Middle Aged
Research Support, Non-U.S. Gov't
Risk factors
Shiga-Like Toxin I
Time Factors
Travel
Water Microbiology
Abstract
In March 1997, an outbreak of Vero cytotoxin-producing Escherichia coli O157 (VTEC) infection occurred amongst holidaymakers returning from Fuerteventura, Canary Islands. For the investigation, a confirmed case was an individual staying in Fuerteventura during March 1997, with either E. coli O157 VTEC isolated in stool, HUS or serological evidence of recent infection; a probable case was an individual with bloody diarrhoea without laboratory confirmation. Local and Europe-wide active case finding was undertaken through national centres, Salm-Net and the European Programme of Intervention Epidemiology, followed by a case-control study. Fourteen confirmed and one probable case were identified from England (7), Finland (5), Wales (1), Sweden (1) and Denmark (1) staying in four hotels. Three of the four hotels were supplied with water from a private well which appeared to be the probable vehicle of transmission. The case-control study showed illness was associated with consumption of raw vegetables (OR 8.4, 95% CI 1-5-48.2) which may have been washed in well water. This investigation shows the importance of international collaboration in the detection and investigation of clusters of enteric infection.
PubMed ID
10579440 View in PubMed
Less detail

Antibodies against hepatitis viruses in merchant seamen.

https://arctichealth.org/en/permalink/ahliterature56804
Source
Scand J Infect Dis. 1995;27(3):191-4
Publication Type
Article
Date
1995
Author
H L Hansen
P L Andersen
L. Brandt
O. Broløs
Author Affiliation
Institute of Maritime Medicine, South Jutland University Centre, Esbjerg, Denmark.
Source
Scand J Infect Dis. 1995;27(3):191-4
Date
1995
Language
English
Publication Type
Article
Keywords
Adult
Aged
Cross-Sectional Studies
Denmark - epidemiology
Enzyme-Linked Immunosorbent Assay
Female
Hepacivirus - immunology
Hepatitis A - epidemiology - immunology - prevention & control
Hepatitis A Antibodies
Hepatitis Antibodies - analysis
Hepatitis B - epidemiology - immunology - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B virus - immunology
Hepatitis C - epidemiology - immunology - prevention & control
Hepatitis C Antibodies - analysis
Hepatovirus - immunology
Humans
Male
Middle Aged
Naval Medicine
Prevalence
Research Support, Non-U.S. Gov't
Risk factors
Sexual Behavior
Travel
Vaccination
Abstract
Seamen constitute a special group of international travellers who may run an increased risk of contracting hepatitis, because of visits to foreign ports and the particular environment on board ship. The purpose of the survey was to assess the prevalence of serological markers for hepatitis A, B and C virus infection among seamen and to identify present and previous risk factors for infection. 515 seamen were studied. The prevalence of antibodies against hepatitis A was 0.3% in subjects below 40 years of age, increasing with age above 40 years, and highest among those who had sailed in international trade. The prevalence of antibodies against hepatitis B was 2.7% in subjects below 40 years of age, increasing to 35.7% in the group above 60 years of age. Hepatitis C antibodies occurred in 1.2%. Vaccination of sailors against hepatitis A should follow the same recommendations as to other travellers. The prevalence of hepatitis B was higher than in reference groups of non-seamen but, because hepatitis B is only one of many blood-borne diseases, prevention should be directed towards changes in behaviour rather than vaccination, except for special groups. Young seamen in international trade were found to be most at risk of contracting sexually transmitted diseases.
PubMed ID
8539539 View in PubMed
Less detail

[A Salmonella epidemic costs 583 days of health insurance and compensation of the carrier of the infection]

https://arctichealth.org/en/permalink/ahliterature75627
Source
Lakartidningen. 1990 Mar 21;87(12):944-5
Publication Type
Article
Date
Mar-21-1990
Author
P. Nolskog
L. Eriksson
S. Elowson
N. Svensson
Author Affiliation
Kliniskt bakteriologiska laboratoriet, Kärnsjukhuset, Skövde.
Source
Lakartidningen. 1990 Mar 21;87(12):944-5
Date
Mar-21-1990
Language
Swedish
Publication Type
Article
Keywords
Carrier State - economics
Humans
Insurance, Health - economics
Salmonella Food Poisoning - economics - epidemiology
Sweden - epidemiology
Travel
PubMed ID
2319848 View in PubMed
Less detail

[A secondary case of hepatitis E. Since 1990 only one of the 17 imported cases was transmitted]

https://arctichealth.org/en/permalink/ahliterature56779
Source
Lakartidningen. 1995 Dec 13;92(50):4807-8
Publication Type
Article
Date
Dec-13-1995
Author
A. Söderström
B. Hammas
L. Magnius
G. Norkrans
Author Affiliation
Infektionskliniken, Ostra sjukhuset, Göteborg.
Source
Lakartidningen. 1995 Dec 13;92(50):4807-8
Date
Dec-13-1995
Language
Swedish
Publication Type
Article
Keywords
Adult
Hepatitis E - diagnosis - immunology - transmission
Humans
Iran - ethnology
Male
Pakistan - epidemiology
Serologic Tests
Sweden - epidemiology
Travel
PubMed ID
8538297 View in PubMed
Less detail

[A traveller to the East is more exposed to the risk of infection].

https://arctichealth.org/en/permalink/ahliterature214098
Source
Lakartidningen. 1995 Oct 11;92(41):3815-8
Publication Type
Article
Date
Oct-11-1995
Author
T O Linglöf
Author Affiliation
Infektionskliniken, Akademiska sjukhuset, Uppsala.
Source
Lakartidningen. 1995 Oct 11;92(41):3815-8
Date
Oct-11-1995
Language
Swedish
Publication Type
Article
Keywords
Bacterial Infections - transmission
Baltic States
Humans
Risk factors
Russia
Travel
Virus Diseases - transmission
PubMed ID
7564637 View in PubMed
Less detail

170 records – page 1 of 17.